Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 11673605.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The antioxidant N-acetylcysteine (NAC) or placebo was administered in a double-blind fashion to patients who met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable AD. Testing for efficacy occurred after 3 and 6 months of treatment. Comparison of interval change favored NAC treatment on nearly every outcome measure, although significant differences were obtained only for a subset of cognitive tasks.
Medical subject headings
- Acetylcysteine
- Alzheimer Disease
- Free Radical Scavengers